---
title: "CITIC International has raised the target price for HENLIUS to RMB 61.98, expecting significant potential in innovative drug development"
description: "CMB International raised the target price of HENLIUS from RMB 20.33 to RMB 61.98, maintaining a \"Buy\" rating. The report pointed out that HENLIUS has the potential to develop from a biosimilar company"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/246006212.md"
published_at: "2025-06-25T03:13:22.000Z"
---

# CITIC International has raised the target price for HENLIUS to RMB 61.98, expecting significant potential in innovative drug development

> CMB International raised the target price of HENLIUS from RMB 20.33 to RMB 61.98, maintaining a "Buy" rating. The report pointed out that HENLIUS has the potential to develop from a biosimilar company into a leading enterprise in the biopharmaceutical field, with promising performance of its innovative drugs under development and expansion of global business through partnerships with pharmaceutical companies. The market authorization applications for HLX14 and HLX11 are under FDA review and are expected to bring overseas revenue to the company

Zhao Yin International published a research report stating that HENLIUS (02696.HK) has the capability to develop from a profitable biosimilar company into a leading enterprise in the biopharmaceutical field. Several innovative drugs under development, including HLX43, HLX22, and Serplulimab, have shown good clinical data performance. The report believes in the company's substantial growth potential, thus raising the target price from HKD 20.33 to HKD 61.98, maintaining a "Buy" rating.

Zhao Yin International believes that HENLIUS is actively expanding its global biosimilar business through collaborations with pharmaceutical companies. Its products "Hanquyou" (Trastuzumab) and Serplulimab have shown strong commercialization performance, while the marketing authorization applications for HLX14 and HLX11 are currently under FDA review, which is expected to open up overseas revenue sources

### Related Stocks

- [02696.HK - HENLIUS](https://longbridge.com/en/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Major work-from-home shake-up proposed for millions of Australians: What it means for you | Should workers who can't WFH get higher pay or extra leave to level the playing field with remote staff? | [Link](https://longbridge.com/en/news/276401093.md) |
| U2 releases song 'American Obituary' honoring Renee Good | U2 has released a song titled "American Obituary" as a tribute to Renee Good, a mother killed by an ICE officer in Minne | [Link](https://longbridge.com/en/news/276275369.md) |
| UK police arrive at home of King Charles' brother Andrew, Telegraph reports | British police arrived at the home of Andrew Mountbatten-Windsor, brother of King Charles, amid allegations he passed co | [Link](https://longbridge.com/en/news/276319933.md) |
| UBTECH Robotics Calls March EGM to Approve 43% Stake in Zhejiang Fenglong Electric | UBTECH Robotics Corp Ltd has scheduled an extraordinary general meeting on March 10, 2026, in Shenzhen to seek sharehold | [Link](https://longbridge.com/en/news/276118745.md) |
| Canada's tactical Ukraine strategy reinforces the North Atlantic | Canada's strategy regarding Ukraine emphasizes the importance of NATO's eastern flank and the security of North Atlantic | [Link](https://longbridge.com/en/news/276463219.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
